Progress of venetoclax in treatment of acute myeloid leukemia
10.3760/cma.j.cn115356-20201214-00304
- VernacularTitle:维奈克拉治疗急性髓系白血病研究进展
- Author:
Xudong WEI
;
Lin CHEN
- From:
Journal of Leukemia & Lymphoma
2021;30(5):257-261
- CountryChina
- Language:Chinese
-
Abstract:
Venetoclax is an important breakthrough in the treatment of acute myeloid leukemia (AML) in recent years. A chemo-free treatment of inducing apoptosis drugs combined with hypomethylating agents is used in the management of AML, which brings hope of long-term survival for the elderly patients or patients who cannot tolerate intensive chemotherapy. However, there are still some patients who are resistant to venetoclax-based regimens. This article introduces the new progress of venetoclax in the treatment of AML in combination with reports at the 62nd American Society of Hematology (ASH) Annual Meeting.
